source
- Merck’s antibody impresses with ‘highly competitive’ data in chronic skin diseaseMerck has revealed detailed data for tulisokibart from a mid-stage trial in hidradenitis suppurativa that analysts say could help carve out a place in a crowded market that already includes AbbVie’…
- House lawmakers hear mixed views on credentialing for psychedelic providersAs psychedelic medicines move closer to market, two members of the U.S. House are outlining how the drugs might be rolled out and what accompanying legislation could look like. The focus of their…